R&D/Clinical Trials

Industry must continue research and development to combat the pandemic.

Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).

Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.

Survey taken by pharma and CRO executives evaluates attributes of large datasets.

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Pharm Exec speaks with Ambrogio about the struggles the industry faces in regard to developing cures for rare cancers, and how Bayer is using precision medicine to meet these challenges.

Pharm Exec speaks with Adams about how his company developed a new medicine designed to meet migraine patients’ needs.

Industry has shown it can overcome challenges en route to creating new therapies.

New mediums of technology must be utilized correctly to reap full benefits.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.

Foster talks to Pharm Exec about why liver disease is on the rise, and Hepion’s new therapy, rencofilstat, in development to treat it.

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

It takes flexibility and adaptability to switch a company’s focus. Here, Alkermes’ Chief Operating Officer Blair Jackson discusses how his team pivoted from developing CNS to oncology therapies and the skills it required.

Rush shares his thoughts on how advanced analytics are making their mark on the pharma industry.

Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.

Opportunity remains despite regulatory and access obstacles.

Recommendations for controlling spend.

Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options.

New technology serves as reminder for the appropriate uses of CRISPR.

Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.